amikacin + amphotericin b + gentamicin + vancomycin

This is a combination of four antimicrobial agents—amikacin, amphotericin B, gentamicin, and vancomycin. Each component has a distinct mechanism of action and spectrum of activity:

• Amikacin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. It is primarily used for serious infections caused by Gram-negative bacteria, including multidrug-resistant strains.
• Gentamicin is also an aminoglycoside with a similar mechanism as amikacin; it targets the 30S ribosomal subunit to inhibit protein synthesis in bacteria. Gentamicin is effective against both Gram-negative and some Gram-positive organisms.
• Vancomycin is a glycopeptide antibiotic that inhibits cell wall synthesis in susceptible bacteria, particularly effective against Gram-positive organisms such as Staphylococcus aureus and Enterococcus species.
• Amphotericin B is a polyene antifungal agent that binds to ergosterol in fungal cell membranes, creating pores that lead to cell death.

This combination would provide extremely broad-spectrum coverage against bacteria (both Gram-negative and Gram-positive) as well as fungi. However, concurrent use of these agents—especially multiple aminoglycosides (amikacin plus gentamicin), or combining nephrotoxic drugs like amphotericin B and vancomycin—is strongly discouraged due to high risk for additive nephrotoxicity and ototoxicity. Such combinations are not standard clinical practice except possibly in rare salvage or empiric regimens under close monitoring.